Wedbush raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $6.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Sangamo Biosciences (SGMO) Announces FDA Fast Track Designation For SB-525 Investigational Hemophilia A Gene TherapyMay 16, 2017 7:33 AM Sangamo Receives Fast Track Designation From The FDA For SB-525 Investigational Hemophilia A Gene TherapyMay 16, 2017 7:30 AM Sangamo Therapeutics Recognizes International MPS Awareness Day And Celebrates The MPS I And MPS II Communities With Stories Of HopeMay 15, 2017 4:01 PM Sangamo Biosciences (SGMO) Presents Recent Developments from Research and Clinical Programs at ASGCTMay 15, 2017 8:02 AM Sangamo Therapeutics Presents Recent Developments from Research and Clinical Programs at Annual Meeting of the American Society of Gene & Cell TherapyMay 15, 2017 8:01 AM Sangamo Biosciences (SGMO) Continues Thursday's MomentumMay 12, 2017 10:54 AM